ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Tea drinkers have lower glaucoma risk

Basic Aromatherapy to Help Balance and Calm

Soy, cruciferous vegetables could help lower breast cancer treatment side effects

The Long-Term Benefits of Drinking Oolong Tea

Why You Should Try This Sweet-Smelling and Health-Boosting Essential Oil

Wonderful White Tea: A Drink Fit for an Emperor

Arnica: This Powerful Herb Promotes Various Kinds of Healing

Chamomile Tea: Why This Ancient Therapeutic Drink Still Stands Out Today

Get ‘Hooked’ on Cat’s Claw: The Many Benefits of This Amazonian Herb

Try Apple Cider Vinegar and Black Cumin Oil as Your Go-To Salad Dressing

 
Print Page
Email Article

Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: A randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety – Source: BMC Medicine, Aug 16, 2010

  [ 14 votes ]   [ Discuss This Article ]
By Alan G Wade, et al. • www.ProHealth.com • August 20, 2010


[Note: To read the full text of this article free, click HERE.]

Background: Melatonin [in regular and timed release form] is extensively used in the USA in a non-regulated manner for sleep disorders.

Prolonged release melatonin (PRM) is licensed in Europe and other countries for the short term treatment of primary insomnia in patients aged 55 years and over.

However, a clear definition of the target patient population and well-controlled studies of long-term efficacy and safety are lacking. It is known that melatonin production declines with age. Some young insomnia patients also may have low melatonin levels.

The study investigated:

• Whether older age or low melatonin excretion is a better predictor of response to PRM,

• Whether the efficacy observed in short-term studies is sustained during continued treatment,

• And the long term safety of such treatment.

Methods: Adult outpatients (791, aged 18-80 years) with primary insomnia, were treated with placebo (2 weeks) and then randomized, double-blind to 3 weeks with PRM or placebo nightly.

PRM patients continued whereas placebo completers were re-randomized 1:1 to PRM or placebo for 26 weeks with 2 weeks of single-blind placebo run-out.

Main outcome measures were sleep latency derived from a sleep diary, Pittsburgh Sleep Quality Index (PSQI), Quality of Life (World Health Organzaton-5) Clinical Global Impression of Improvement (CGI-I) and adverse effects and vital signs recorded at each visit.

Results:
On the primary efficacy variable sleep latency:

• The effects of PRM (3 weeks) in patients with low endogenous melatonin (6-sulphatoxymelatonin [6-SMT] 8 g/night) regardless of age did not differ from the placebo,

• Whereas PRM significantly reduced sleep latency compared to the placebo in elderly patients regardless of melatonin levels (-19.1 versus -1.7 min; P=0.002).

• The effects on sleep latency - and additional sleep and daytime parameters that improved with PRM - were maintained or enhanced over the 6-month period with no signs of tolerance.

Most adverse events were mild in severity with no clinically relevant differences between PRM and placebo for any safety outcome.

Conclusions:
• The results demonstrate short- and long-term efficacy and safety of PRM in elderly insomnia patients.

• Low melatonin production regardless of age is not useful in predicting responses to melatonin therapy in insomnia.

• The age cut-off for response warrants further investigation.

Source: BMC Medicine, Aug 16, 2010;8(1):51. PMID: 20712869, by Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N. CPS Research and Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK; Neurim Pharmaceuticals Ltd. and Department of Neurobiology, Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel. [Email: alangwade@fastmail.fm]





Post a Comment

Featured Products From the ProHealth Store
Optimized Curcumin Longvida® Energy NADH™ 12.5mg Ultra EPA  - Fish Oil


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Melatonin Sublingual Tablets Melatonin Sublingual Tablets
Supports Deep, Restful Sleep Naturally
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

D-ficient? Health Risks You Need to Know About D-ficient? Health Risks You Need to Know About
How Glutathione Can Save Your Life How Glutathione Can Save Your Life
Secret Nutrient for Radiant Skin Secret Nutrient for Radiant Skin
How I Found My Long-Lost Energy How I Found My Long-Lost Energy
Curcumin - a Golden Gift of Nature with Benefits Still Untold Curcumin - a Golden Gift of Nature with Benefits Still Untold

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2018 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map